Researchers are excitedly focused on retatrutide, a promising treatment created by Eli Lilly, as a significant advance in body reduction . Distinct from many previous approaches, retatrutide is a twin-action compound targeting equally GLP-1 and GIP, hormones that affect satiety and glucose balanc